Literature DB >> 22190999

Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma Cells.

Christopher Scott Berger1, John W Marks, Robert D Bolskar, Michael G Rosenblum, Lon J Wilson.   

Abstract

Fullerene (C(60))-monoclonal antibody (mAb) immunoconjugates have been determined to internalize into target cells using water-soluble Gd(3+) ion-filled metallofullerenes (Gd@C(60)[OH](x)). Two separate conjugations of Gd@C(60)(OH)(x) with the antibody ZME-018 and a murine antibody mixture (MuIgG) were performed in a 1:5 mAb/Gd@C(60) ratio. Characterization of the immunoconjugates was established using inductively coupled plasma mass spectrometry (ICP-MS) for Gd(3+) and UV-Vis spectrometry (for Gd@C(60) + C(60)). Once conjugated, enzyme-linked immunosorbent assays showed little change in the specific binding of ZME-018. Each immunoconjugate was exposed to two cancer cell lines, A375m (antigen positive), and T24, bladder carcinoma (antigen negative). Internalization levels of the immunoconjugate were determined at various time points during 24 hours by harvesting and digesting the cells with 70% HNO(3) for Gd(3+) ion analysis by ICP-MS. These results are the first to demonstrate the practicality of a targeted cancer therapy based on fullerene immunotherapy.

Entities:  

Year:  2011        PMID: 22190999      PMCID: PMC3243658          DOI: 10.1593/tlo.11157

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  34 in total

1.  In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers.

Authors:  D W Cagle; S J Kennel; S Mirzadeh; J M Alford; L J Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Highly-iodinated fullerene as a contrast agent for X-ray imaging.

Authors:  Tim Wharton; Lon J Wilson
Journal:  Bioorg Med Chem       Date:  2002-11       Impact factor: 3.641

Review 3.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 4.  Detecting and treating cancer with nanotechnology.

Authors:  Keith B Hartman; Lon J Wilson; Michael G Rosenblum
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  Target-selective photo-degradation of HIV-1 protease by a fullerene-sugar hybrid.

Authors:  Shuho Tanimoto; Satoshi Sakai; Shuichi Matsumura; Daisuke Takahashi; Kazunobu Toshima
Journal:  Chem Commun (Camb)       Date:  2008-10-02       Impact factor: 6.222

6.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

7.  Superparamagnetic gadonanotubes are high-performance MRI contrast agents.

Authors:  B Sitharaman; K R Kissell; K B Hartman; L A Tran; A Baikalov; I Rusakova; Y Sun; H A Khant; S J Ludtke; W Chiu; S Laus; E Tóth; L Helm; A E Merbach; L J Wilson
Journal:  Chem Commun (Camb)       Date:  2005-07-08       Impact factor: 6.222

8.  Synthesis, structural characterization, and immunological properties of carbon nanotubes functionalized with peptides.

Authors:  Davide Pantarotto; Charalambos D Partidos; Roland Graff; Johan Hoebeke; Jean-Paul Briand; Maurizio Prato; Alberto Bianco
Journal:  J Am Chem Soc       Date:  2003-05-21       Impact factor: 15.419

Review 9.  Gadofullerene MRI contrast agents.

Authors:  Robert D Bolskar
Journal:  Nanomedicine (Lond)       Date:  2008-04       Impact factor: 5.307

10.  Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma.

Authors:  F Buchegger; C Antonescu; A Bischof Delaloye; C Helg; T Kovacsovics; M Kosinski; J-P Mach; N Ketterer
Journal:  Br J Cancer       Date:  2006-05-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.